LETTER TO THE EDITOR

A novel histone deacetylase inhibitor exerts promising anti-breast cancer activity via triggering AIFM1-dependent programmed necrosis

Dear Editor,

Breast cancer is one of the most lethal cancers in women, with many patients still succumbing to this disease [1]. Accumulating evidence demonstrates that histone deacetylase inhibitors (HDACIs) are a promising therapeutic intervention for breast cancer [2], and many of them have shown favorable anti-cancer activities in both preclinical and clinical settings [3]. However, most current HDACIs only exhibit limited efficacy against solid tumors with toxic side effects and readily produce drug resistance [4]. Therefore, it is necessary to develop new HDACIs with improved anti-tumor activities and decreased toxicities for breast cancer therapeutics and investigate their mechanism of action.

To improve the physicochemical properties of new generation HDACIs, the coumarin unit, as a promising pharmacophore in anti-cancer drug discovery, was incorporated into hydroxamate HDACIs, and a series of new coumarin-based derivatives were synthesized. After our initial screening, a compound coded YF349 with excellent HDAC inhibitory activity was identified (Supplementary Figure S1A, B). A hallmark index of HDAC inhibition is the increased acetylation of histones H3 and H4 [5]. As shown in Supplementary Figure SIC, D, YF349 significantly increased the acetylation of hH3 and Ac-H4 compared with Suberoylanilide Hydroxamic Acid (SAHA). SAHA was used as a positive control in our experiments, as it is the first HDACI approved by the US Food and Drug Administration (FDA) for the clinical treatment of breast cancer [6]. Collectively, these results suggested that YF349 was a bona fide HDACI and had potential anti-breast cancer activity.

The chemical structure of YF349 is shown in Figure 1A. We next examined the anti-breast cancer activity of YF349 in vitro. As shown in Figure 1B, YF349 significantly inhibited the growth of breast cancer cells compared with SAHA. In addition, YF349 significantly inhibited colony formation and the invasion ability of breast cancer cells (Figure1C, D and Supplementary Figure S2A). Additionally, YF349 induced obvious cell death in breast cancer cells compared with SAHA treatment at the same dosage (Figure 1E). Finally, YF349 significantly altered the expression of proliferation cell nuclear antigen (PCNA), apoptosis-related proteins (cleaved-poly ADP-ribose polymerase [PARP]), and epithelial–mesenchymal transition (EMT)-related proteins (Supplementary Figure S2B). We then investigated the anti-breast cancer effect of YF349 in vivo. As shown in Figure 1F, G and Supplementary Figure S2C-E, YF349 significantly inhibited the tumor growth and metastasis compared with the control group and SAHA treatment at the same concentration. Meanwhile, YF349 significantly increased the levels of Ac-H3 and Ac-H3, which confirmed the HDAC inhibitory effect of YF349 on breast cancer in vivo (Supplementary Figure S2F). We then sought to investigate the potential toxicity of YF349. As shown in Supplementary Figure S3A, B, no significant changes in body weight and the major organs of mice treated with YF349 were observed. Histological analyses revealed no obvious damage to major organs (Supplementary Figure S3C). In addition, levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are representative indicators of liver function, and blood urea nitrogen (BUN) is an indicator of kidney and

Abbreviations: Ac-H3, acetylation-histone 3; Ac-H4, acetylation-histone 4; AIFM1, apoptosis inducing factor, mitochondrion-associated, 1; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen; CypA, Cyclophilin A; DAPI, 4’, 6-diamidino-2-phenylindole; DMSO, dimethyl sulfoxide; EMT, epithelial–mesenchymal transition; FDA, Food and Drug Administration; HDAC, histone deacetylase; HDACI, histone deacetylase inhibitor; HMGB1, high mobility group protein 1 (HMGB1); LDH, lactate dehydrogenase; PCNA, proliferation cell nuclear antigen; PI, propidium iodide; RT-PCR, reverse transcription-polymerase chain reaction; SAHA, suberoylanilide hydroxamic acid; siRNA, short interfering RNA; TEM, transmission electron microscope; ZBG, Zn binding group.

Peipei Shan and Feifei Yang contributed equally to this work.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2022 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.
FIGURE 1  YF349 exerts promising anti-breast cancer activity by triggering AIFM1-dependent programmed necrosis. (A) Chemical structure of the new HDACI, YF349. (B) Breast cancer cells (MDA-MB231 and 4T1) were treated with YF349 or SAHA. After 48 h, MTS assay was performed. The bars indicate mean ± SD. (C) MDA-MB231 and 4T1 cells were seeded on 6-well plates. After 12 h, cells were treated with...
liver conditions. As shown in Supplementary Figure S3D, YF349 treatment did not significantly affect the ALT, AST and BUN levels. Taken together, these results indicate that YF349 significantly inhibited breast cancer cell growth and metastasis both in vitro and in vivo and showed few adverse effects on the experimental mice at a therapeutic concentration.

We then identified the modality of breast cancer cell death caused by YF349. As shown in Supplementary Figure S4A, a significant portion of cells appeared necrotic, and the cell death modality induced by YF349 was similar to that caused by the necrosis-inducer shikonin. Moreover, pretreatment with the pan-caspase inhibitor z-VAD-fmk did not prevent YF349-induced cell death, while this treatment inhibited the proteasome inhibitor MG132-induced cell death (Supplementary Figure S4B). In addition, cells treated with YF349 presented smeared DNA bands on an agarose gel in the DNA large fragment assay (Supplementary Figure S4C). The morphological characteristics of necrosis were also confirmed by transmission electron microscope (TEM) under YF349 treatment (Supplementary Figure S4D). In addition, YF349 promoted the cellular release of high mobility group protein B1 (HMGB1) and lactate dehydrogenase (LDH), which were shown to be necrosis markers [7] (Supplementary Figure S4E, F). Moreover, increased concentration of YF349 significantly upregulated the proportion of necrotic cells (Supplementary Figure S4G). Overall, these results indicated that YF349 induced necrosis in breast cancer cells.

To further explore the detailed mechanisms of the anti-breast cancer effect of YF349. RNA-sequencing analysis was performed to identify differentially expressed genes between MDA-MB231 cells treated with or without YF349. Supplementary Table S1 shows the differentially expressed genes after YF349 treatment. We then analyzed the top 10 upregulated genes (cut-off, fold change > 4.8 and \( P < 0.05 \)) listed in Supplementary Table S1. As shown in Supplementary Figure S5A, among the top 10 upregulated genes, the mRNA level of AIFM1 (apoptosis-inducing factor, mitochondrion-associated, 1) was significantly increased upon YF349 treatment compared with other genes. Supplementary Figure S4 showed that YF349 induced obvious necrosis of breast cancer cells, and AIFM1 has been known to be a key regulator of necrosis [8]. Therefore, we speculated that AIFM1 may play an essential role in the anti-tumor effect of YF349 on breast cancer.

A previous study reported that the increased total AIFM1 expression in cells led to increased sensitivity to cell death [9]. As shown in Figure 1H, YF349 significantly increased the mRNA level of AIFM1. An earlier study has demonstrated that HDAC1 could bind to the promoter region of AIFM1 and thus repress AIFM1 expression [10]. The molecular docking model showed that YF349 could interact with the active site of HDAC1 (Supplementary Figure S5B). These findings provide evidence that the increased mRNA level of AIFM1 induced by YF349 may be through the competitive interference of HDAC1 binding with the active site of HDAC1.
to the promoter of AIFM1. As shown in Figure 1I, J and Supplementary Figure S5C-E, the promoter activity of AIFM1 was significantly upregulated by YF349, and YF349 significantly disrupted the binding of HDAC1 to the AIFM1 promoter. Taken together, these results indicated that YF349 upregulated the AIFM1 expression by disrupting HDAC1 binding to the AIFM1 promoter.

We then clarified the role of AIFM1 in the YF349-induced necrosis in breast cancer cells. As shown in Figure 1K-M and Supplementary Figure S6A, B, AIFM1 knockdown cells were less sensitive to YF349-induced necrosis. These results indicated that YF349 induced necrosis of breast cancer cells is in an AIFM1-dependent manner. Furthermore, we found that YF349 promoted the formation of the AIFM1-Cyclophilin A (CypA)-γH2Ax complex in breast cancer cells (Figure 1N-P and Supplementary Figure S6C, D). Collectively, these results demonstrated that YF349 remarkably induced the nuclear translocation of AIFM1 and significantly promoted the formation of the AIFM1-CypA-γH2Ax complex.

In conclusion, we identified a novel HDACI, YF349, which displayed promising anti-breast cancer activity both in vitro and in vivo. Further mechanistic studies revealed that YF349 increased the AIFM1 expression via inducing the disassociation of HDAC1 from the AIFM1 promoter, subsequently accelerating the nuclear translocation of AIFM1, promoting the formation of AIFM1-CypA-γH2Ax complex, and finally inducing AIFM1-mediated necrosis of breast cancer cells. Collectively, our work highlighted the anti-breast cancer therapeutic potential of a new HDACI, YF349, via triggering AIFM1-dependent necrosis. Our results suggest that the HDAC1-AIFM1-CypA-γH2Ax signal axis can be a novel therapeutic target of breast cancer, and YF349 could be a promising preclinical drug candidate for breast cancer treatment.

AUTHOR CONTRIBUTIONS
Author contributions: PPS contributed to experimental design, data acquisition, analysis and interpretation and drafted the manuscript. FFY contributed to data acquisition, analysis and interpretation, and drafted the manuscript. PPS made sequencing and statistical analysis. JY and LRW collected clinical data and collected samples. YHQ and HRQ participated in the synthesis and purification of target compounds. PPS and LRW performed the animal experiments, model improvement and data analysis. HZ and SJZ contributed to the conception, experimental design, data interpretation, and critical revision of the manuscript. All authors reviewed and edited the manuscript. All authors read and approved the final manuscript.

ACKNOWLEDGMENTS
We thank Cuiyun Liu from The Affiliated Hospital of Qingdao University for supporting this study and for guidance and insightful discussions; We thank Yanyan Gao from the Institute of Translational Medicine, Qingdao University for technical support; We thank the participants and staff of Shanghai Key Laboratory of Regulatory Biology, Institute of Biomedical Sciences and School of Life Sciences, East China Normal University.

COMPETING INTERESTS
The authors declare that they have no competing interests.

FUNDING
This work was supported by the National Natural Science Foundation of China (No. 91849209, 81803016, 81703360, 81903539); the Natural Science Foundation of Shandong Province (No. ZR2019HB012, ZR2021MC189); the China Postdoctoral Science Foundation (No. 2019M650157).

AVAILABILITY OF DATA AND MATERIALS
All data needed to evaluate the conclusions are presented in the paper or the Supplementary Materials. The raw data of the RNA-seq results were submitted to the Gene Expression Omnibus database, with the approval number of GSE203025.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE
All animal experiments were performed according to the guidelines approved by the Institutional Animal Care and performed following the guidelines for Animal Experimentation of Qingdao University and approved by the Ethics Committee of Medical College of Qingdao University (QDU-AEC-2022093).

Peipei Shan1
Feifei Yang2
Jie Yu3
Lirong Wang1
Yuhua Qu2
Huiran Qiu3
Hua Zhang2
Sujie Zhu1

1Institute of Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University, Qingdao, Shandong 266021, P. R. China
2School of Biological Science and Technology, University of Jinan, Jinan, Shandong 250022, P. R. China
3Qingdao Center Hospital: Qingdao Center Medical Group, Qingdao, Shandong 266042, P. R. China
Correspondence
Peipei Shan, Institute of Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University. Qingdao 266021, P. R. China
Email: shanpeipei@qdu.edu.cn

Sujie Zhu, Institute of Translational Medicine, The Affiliated Hospital of Qingdao University, College of Medicine, Qingdao University. Qingdao 266021, P. R. China.
Email: zhusujie@qdu.edu.cn

Hua Zhang, School of Biological Science and Technology, University of Jinan, Jinan 250022, P. R. China.
Email: bio_zhangh@ujn.edu.cn

ORCID
Peipei Shan https://orcid.org/0000-0002-0553-4728

REFERENCES
1. Cesca MG, Vian L, Cristovao-Ferreira S, Ponde N, de Azambuja E. HER2-positive advanced breast cancer treatment in 2020. Cancer Treat Rev. 2020;88:102033.
2. Huang M, Zhang J, Yan C, Li X, Zhang J, Ling R. Small molecule HDAC inhibitors: Promising agents for breast cancer treatment. Bioorg Chem. 2019;91:103184.
3. Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol. 2012;90(1):85–94.
4. Qiu T, Zhou L, Zhu W, Wang T, Wang J, Shu Y, et al. Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials. Future Oncol. 2013;9(2):255–69.
5. Somech R, Izraeli S, A JS. Histone deacetylase inhibitors—a new tool to treat cancer. Cancer Treat Rev. 2004;30(5):461–72.
6. Mann BS, Johnson JR, Cohen MH, Justice R, Pazdur R. FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma. Oncologist. 2007;12(10):1247–52.
7. Minsart C, Liefferinckx C, Lemmers A, Dressen C, Quertinmont E, Leclercq I, et al. New insights in acetaminophen toxicity: HMGB1 contributes by itself to amplify hepatocyte necrosis in vitro through the TLR4-TRIF-RIPK3 axis. Sci Rep. 2020;10(1):5557.
8. Artus C, Boujrad H, Bouharrour A, Brunelle MN, Hoos S, Yuste VJ, et al. AIF promotes chromatinolysis and caspase-independent programmed necrosis by interacting with histone H2AX. EMBO J. 2010;29(9):1585–99.
9. Joza N, Susin SA, Daugas E, Stanford WL, Cho SK, Li CY, et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature. 2001;410(6828):549–54.
10. Burton TR, Eisenstat DD, Gibson SB. BNIP3 (Bcl-2 19 kDa interacting protein) acts as transcriptional repressor of apoptosis-inducing factor expression preventing cell death in human malignant gliomas. J Neurosci. 2009;29(13):4189–99.

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.